论文部分内容阅读
Stopping antimalarial chemoprophylaxis can be followed by increased risk of ma laria, suggesting that it interferes with the development of antimalarial immuni ty. We report analysis of extended follow-up until age 2 years of a randomised, placebo-controlled double-blind trial of intermittent preventive antimalarial treatment in infants. The rate of clinical malaria (events per person-year at risk, starting 1 month after final dose of intermittent treatment)-was 0.28 in the sulfadoxine-pyrimethamine group and 0.43 in the placebo group (protective e ffect 36%, 95%CI 11-53). Intermittent treatment produced a sustained reductio n in the risk of clinical malaria extending well beyond the duration of the phar macological effects of the drugs, excluding a so-called rebound effect and sugg esting that such treatment could facilitate development of immunity against Plas modium falciparum.
Suggesting that it interferes with the development of antimalarial immuni ty. We report analysis of extended follow-up until age 2 years of a randomized, placebo-controlled double-blind trial of intermittent preventive antimalarial treatment in infants. The rate of clinical malaria (events per person-year at risk, starting 1 month after final dose of intermittent treatment) -was 0.28 in the sulfadoxine-pyrimethamine group and 0.43 in the placebo group %, 95% CI 11-53). Intermittent treatment produced a sustained reduction in the risk of clinical malaria extending beyond beyond the duration of the phar macological effects of the drugs, excluding a so-called rebound effect and sugg esting that such treatment could facilitate development of immunity against Plasmodium falciparum.